ArticleCureus2026
Gamma-Delta Hepatosplenic T-Cell Lymphoma in a Two-Year-Old: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gamma-delta (γδ) hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive malignancy that is exceptionally uncommon in young children. It often presents with nonspecific symptoms that delay diagnosis. We describe a previously healthy 26-month-old girl who developed daily fevers, weight loss, decreased appetite, and progressive lower-extremity weakness leading to loss of ambulation. Examination revealed marked hepatosplenomegaly without lymphadenopathy, and laboratory studies showed lymphocytic leukocytosis with evolving cytopenias. Bone marrow evaluation identified a clonal γδ T-cell population, and liver biopsy confirmed sinusoidal infiltration, establishing the diagnosis of γδ HSTCL. Her clinical course was characterized by poor response to multiple induction, consolidation, and targeted therapies. She presented with persistent minimal residual disease (MRD), requiring repeated treatment escalation and substantial supportive care. This case illustrates the diagnostic difficulty and therapeutic resistance of pediatric γδ HSTCL. Early recognition, molecular characterization, and timely consideration of possible stem cell transplant are essential to improving outcomes in this rare and highly aggressive pediatric lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.